Draffan G H, Lewis P J, Firmin J L, Jordan T W, Dollery C T
Br J Clin Pharmacol. 1976 Jun;3(3):489-95. doi: 10.1111/j.1365-2125.1976.tb00626.x.
1 The fate of oral and intravenous indoramin has been studied after single doses in man using the 14C labelled drug. Plasma concentrations of indoramin have been determined during chronic oral antihypertensive therapy employing a stable isotope dilution assay. 2 Following singleoral dosing the drug is well absorbed and extensively metabolised. Faecal excretion in 72 h accounts for 46% of the administered radioactivity of which approximately 4% is associated with indoramin. Less than 2% of the radioactivity in urine is accountable as the concentration of total metabolites. Peak plasma levels both of drug and metabolites occur 1-2 h after dosing, the maximal lowering of blood pressure occurring at this time. 3 The clearance of indoramin, determined after intravenous administration is of the same order as liver blood flow. In the isolated perfused rat liver, the extraction ratio is 0.98.
1 使用14C标记的药物,在人体中单次给药后研究了口服和静脉注射吲哚拉明的转归。采用稳定同位素稀释分析法,在慢性口服抗高血压治疗期间测定了吲哚拉明的血浆浓度。2 单次口服给药后,药物吸收良好且广泛代谢。72小时内粪便排泄占给药放射性的46%,其中约4%与吲哚拉明有关。尿液中放射性不到2%可归因于总代谢产物的浓度。给药后1-2小时出现药物和代谢产物的血浆峰值水平,此时血压最大程度降低。3 静脉给药后测定的吲哚拉明清除率与肝血流量处于同一水平。在离体灌注大鼠肝脏中,提取率为0.98。